

12<sup>th</sup> November, 2020

To

BSE Limited  
Corporate Relationship Department  
P J Towers  
Dalal Street, Fort  
Mumbai – 400 001.

Dear Sir/Madam,

**Sub:** Outcome of Board Meeting held on 12<sup>th</sup> November, 2020

**Ref:** Security Code: 524520; Security ID; KMCSHIL

This is to inform you that the Board of Directors at their meeting held today, the 12<sup>th</sup> November, 2020 approved the Standalone Unaudited Financial results for the Quarter and half year ended 30<sup>th</sup> September, 2020 along with the Limited Review Report of the Auditors, copy of which is enclosed for your records.

We hereby inform you that the Board Meeting commenced at 11.30 AM and concluded at 12.20 PM.

Thank You

With regards,

For **KMC SPECIALITY HOSPITALS (INDIA) LIMITED**



**Dr S Manivannan**  
Managing Director



**Regd. Office :**  
**KMC Speciality Hospitals (India) Ltd.,**  
CIN · L85110TN1982PLC009781  
6, Royal Road, Cantonment, Trichy - 620 001.  
P 0431 - 4077777, F 0431 - 2415402  
E info@kauveryhospital.com | W www.kauveryhospital.com



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS**

**TO THE BOARD OF DIRECTORS OF KMC SPECIALITY HOSPITALS (INDIA) LIMITED**

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **KMC SPECIALITY HOSPITALS (INDIA) LIMITED** ("the Company"), for the quarter and half year ended September 30, 2020 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**  
Chartered Accountants  
(Firm's Registration No. 008072S)



**Ananthi Amarnath**  
Partner

Membership No. 209252  
UDIN: 20209252AAAAJH2881

**Place:** Chennai  
**Date:** November 12, 2020

Statement of unaudited financial results for the Quarter and Half year Ended September 30, 2020

(Rs. in Lakhs except EPS)

| Particulars  | Quarter ended                     |                              |                                   | Half year ended                   |                                   | Year ended                  |
|--|-----------------------------------|------------------------------|-----------------------------------|-----------------------------------|-----------------------------------|-----------------------------|
|  | September 30, 2020<br>(Unaudited) | June 30, 2020<br>(Unaudited) | September 30, 2019<br>(Unaudited) | September 30, 2020<br>(Unaudited) | September 30, 2019<br>(Unaudited) | March 31, 2020<br>(Audited) |
| <b>1 Income</b>  |                                   |                              |                                   |                                   |                                   |                             |
| a) Revenue from operations   | 2,542.82                          | 1,829.75                     | 2,384.73                          | 4,372.57                          | 4,634.75                          | 9,618.01                    |
| b) Other income  | 49.27                             | 27.29                        | 35.15                             | 76.56                             | 63.69                             | 141.72                      |
| <b>Total Income</b>  | <b>2,592.09</b>                   | <b>1,857.04</b>              | <b>2,419.88</b>                   | <b>4,449.13</b>                   | <b>4,698.44</b>                   | <b>9,759.73</b>             |
| <b>2 Expenses</b>  |                                   |                              |                                   |                                   |                                   |                             |
| a) Cost of materials consumed                                      | 71.47                             | 45.94                        | 14.76                             | 117.41                            | 54.09                             | 145.43                      |
| b) Purchase of traded goods  | 375.45                            | 207.06                       | 280.33                            | 582.51                            | 555.96                            | 1,299.32                    |
| c) Changes in inventory of traded goods                            | (32.71)                           | 36.06                        | (21.49)                           | 3.35                              | (17.82)                           | (65.07)                     |
| d) Employee benefits expense                                       | 539.31                            | 519.08                       | 513.39                            | 1,058.39                          | 1,041.11                          | 2,158.41                    |
| e) Finance costs   | 17.00                             | 27.55                        | 22.83                             | 44.55                             | 45.80                             | 86.08                       |
| f) Depreciation and amortisation expense                           | 149.04                            | 128.84                       | 117.06                            | 277.88                            | 225.54                            | 494.79                      |
| g) Other expenses  | 1,084.53                          | 817.38                       | 1,037.05                          | 1,901.91                          | 1,962.77                          | 3,971.30                    |
| <b>Total expenses</b>  | <b>2,204.09</b>                   | <b>1,781.91</b>              | <b>1,983.95</b>                   | <b>3,986.00</b>                   | <b>3,887.45</b>                   | <b>8,090.28</b>             |
| <b>3 Profit before tax (1-2)</b>                                   | <b>388.00</b>                     | <b>75.13</b>                 | <b>435.93</b>                     | <b>463.13</b>                     | <b>810.99</b>                     | <b>1,669.47</b>             |
| <b>4 Income tax expense</b>  |                                   |                              |                                   |                                   |                                   |                             |
| a) Current tax   | 110.87                            | 49.55                        | 93.51                             | 160.42                            | 219.45                            | 535.26                      |
| b) Deferred tax  | (0.59)                            | (27.29)                      | 31.09                             | (27.88)                           | 14.00                             | (40.05)                     |
| <b>Total income tax expense</b>                                    | <b>110.28</b>                     | <b>22.26</b>                 | <b>124.60</b>                     | <b>132.54</b>                     | <b>233.45</b>                     | <b>495.21</b>               |
| <b>5 Profit after tax (3-4)</b>                                    | <b>277.72</b>                     | <b>52.87</b>                 | <b>311.33</b>                     | <b>330.59</b>                     | <b>577.54</b>                     | <b>1,174.26</b>             |
| <b>6 Other comprehensive income / (loss)</b>                       |                                   |                              |                                   |                                   |                                   |                             |
| Items that will not be reclassified subsequently to profit or loss |                                   |                              |                                   |                                   |                                   |                             |
| (a) Re-measurement of defined benefit plans                        | (4.41)                            | (2.23)                       | (10.23)                           | (6.64)                            | (8.25)                            | (22.18)                     |
| (b) Income tax effect  | 1.26                              | (0.65)                       | 2.98                              | 1.93                              | 2.40                              | 6.46                        |
| <b>Total other comprehensive income / (loss), net of tax</b>       | <b>(3.13)</b>                     | <b>(2.88)</b>                | <b>(7.25)</b>                     | <b>(4.71)</b>                     | <b>(5.85)</b>                     | <b>(15.72)</b>              |
| <b>7 Total comprehensive income, net of tax (5+6)</b>              | <b>274.59</b>                     | <b>49.99</b>                 | <b>324.08</b>                     | <b>325.88</b>                     | <b>571.69</b>                     | <b>1,158.54</b>             |
| <b>8 Paid-up equity share capital (Face value of Re. 1/- each)</b> | <b>1,830.85</b>                   | <b>1,830.85</b>              | <b>1,830.85</b>                   | <b>1,830.85</b>                   | <b>1,830.85</b>                   | <b>1,830.85</b>             |
| <b>9 Reserves i.e. Other equity</b>                                |                                   |                              |                                   |                                   |                                   | <b>3,434.83</b>             |
| <b>10 Earnings per share (EPS) of Re. 1/- each :</b>               |                                   |                              |                                   |                                   |                                   |                             |
| Basic and diluted EPS  | 0.17                              | 0.03                         | 0.20                              | 0.20                              | 0.37                              | 0.72                        |
|  | (Not annualised)                  | (Not annualised)             | (Not annualised)                  | (Not annualised)                  | (Not annualised)                  | (Annualised)                |

Statement of assets and liabilities

(Rs. in Lakhs)

| Particulars   | As at                             | As at                       |
|---|-----------------------------------|-----------------------------|
|   | September 30, 2020<br>(Unaudited) | March 31, 2020<br>(Audited) |
| <b>A Assets</b>   |                                   |                             |
| <b>1 Non-current assets</b>   |                                   |                             |
| (a) Property, plant and equipment   | 7,224.79                          | 3,754.90                    |
| (b) Right-of-Use-Assets   | 186.86                            | 83.55                       |
| (c) Capital work in progress  | 23.30                             | 7.06                        |
| (d) Investment property   | 40.43                             | 40.43                       |
| (e) Intangible assets   | 49.32                             | 81.95                       |
| (f) Financial assets  |                                   |                             |
| Investments   | 0.38                              | 0.28                        |
| Loans   | 376.57                            | 393.42                      |
| Other financial assets  | 5.88                              | 7.68                        |
| (g) Deferred tax asset (net)  | 388.87                            | 359.08                      |
| (h) Income tax assets (net)   | 71.43                             | 80.62                       |
| (i) Other assets  | 20.91                             | 440.17                      |
| <b>Sub-total - Non-current assets</b>   | <b>8,388.74</b>                   | <b>5,229.12</b>             |
| <b>2 Current assets</b>   |                                   |                             |
| (a) Inventories   | 199.64                            | 222.29                      |
| (b) Financial assets  |                                   |                             |
| Trade receivables   | 412.82                            | 209.86                      |
| Cash and cash equivalents   | 77.11                             | 111.97                      |
| Other bank balances   | 472.26                            | 887.12                      |
| Loans   | 138.95                            | 113.29                      |
| Other financial assets  | 163.33                            | 154.65                      |
| (c) Other assets  | 117.04                            | 71.07                       |
| <b>Sub-total - Current assets</b>   | <b>1,581.25</b>                   | <b>1,778.35</b>             |
| <b>Total - Assets</b>   | <b>9,969.99</b>                   | <b>6,999.47</b>             |
| <b>Equity and liabilities</b>   |                                   |                             |
| <b>1 Equity</b>   |                                   |                             |
| (a) Equity share capital  | 1,830.85                          | 1,830.85                    |
| (b) Other equity  | 3,760.73                          | 3,434.83                    |
| <b>Sub-total - Equity</b>   | <b>5,391.58</b>                   | <b>5,065.68</b>             |
| <b>2 Non-current liabilities</b>  |                                   |                             |
| (a) Financial Liabilities   |                                   |                             |
| Borrowings  | 2,793.25                          | 579.52                      |
| Lease Liabilities   | 177.58                            | 66.56                       |
| Other financial liabilities   | 5.81                              | 8.05                        |
| (b) Provisions  | 65.00                             | 41.04                       |
| <b>Sub-total - Non-current liabilities</b>                                      | <b>3,041.64</b>                   | <b>695.17</b>               |
| <b>3 Current liabilities</b>  |                                   |                             |
| (a) Financial Liabilities   |                                   |                             |
| Lease Liabilities   | 16.95                             | 19.00                       |
| Trade payables  |                                   |                             |
| (i) Total outstanding dues of micro and small enterprises                       | 9.45                              | 8.83                        |
| (ii) Total outstanding dues of creditors other than micro and small enterprises | 659.06                            | 426.07                      |
| Other financial liabilities   | 480.77                            | 501.62                      |
| (b) Other liabilities   | 195.01                            | 145.19                      |
| (c) Provisions  | 175.73                            | 137.91                      |
| <b>Sub-total - Current liabilities</b>  | <b>1,536.97</b>                   | <b>1,238.62</b>             |
| <b>Total - Equity and liabilities</b>   | <b>9,969.99</b>                   | <b>6,999.47</b>             |

H

Handwritten signature/initials in blue ink.



Notes:

- 1 The statement of unaudited financial results for the quarter and half year ended September 30, 2020, in respect of KMC Speciality Hospitals (India) Limited ("the Company") has been reviewed by Audit Committee and approved by the Board of Directors on November 12, 2020. The above results are subjected to limited review by the statutory auditors of the Company.
- 2 These financial results have been prepared in accordance with Indian Accounting Standard ("Ind AS") prescribed under section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Circular dated July 5, 2016.
- 3 The Company operates in a single segment i.e. "Medical and Healthcare Services" and hence does not have any additional disclosures to be made under IND AS 108 - Operating Segment.
- 4 The Company has considered internal and certain external sources of information including credit reports, economic forecasts and industry reports up to the date of approval of the financial results in determining the impact on various elements of its financial results relating to COVID-19 pandemic. The Company has used the principles of prudence in applying judgments, estimates and assumptions including sensitivity analysis and based on the current estimates, the Company expects to fully recover the carrying amount of trade receivables, inventories, other financial assets and other current assets. The eventual outcome of impact of the global health pandemic may be different from those estimated as on the date of approval of these financial results.
- 5 The Company's operations for the period ended September 30, 2020 were impacted on account of outbreak of COVID-19 pandemic. The results for the period are therefore, not comparable with those of the previous periods.
- 6 The Code on Wages, 2019 and Code on Social Security, 2020 "the Codes" relating to employee compensation and post-employment benefits that received the Presidential Assent have not been notified. Further, the related rules for quantifying the financial impact have not been notified. The Company will assess the impact of the Codes when the rules are notified and will record any related impact in the Codes become effective.

Place Chennai  
Date: November 12, 2020



Dr. S. Manivannan  
Managing Director  
DIN: 00910804

**KMC Speciality Hospitals (India) Limited**  
**Regd. Office: 6, Royal Road, Cantonment, Trichy - 620 001**  
**Corporate Identity Number: L85110TN1982PLC009781**  
**Statement of Unaudited financial results for the Quarter and Half year Ended September 30, 2020**

**Statement of Cash flows**

|   | (Rs. in Lakhs)                             |  |
|---|--|--|
|   | For the period ended<br>September 30, 2020 | For the period ended<br>September 30, 2019 |
| <b>A Cash flows from operating activities</b>                         |  |  |
| Net Profit before taxation  | 463.13                                     | 830.99                                     |
| Operating profit before working capital changes                       | 777.08                                     | 1,118.04                                   |
| <b>Net cash from operating activities</b>                             | <b>1,065.50</b>                            | <b>534.74</b>                              |
| <b>B Cash flow used in investing activities</b>                       | <b>(3,256.25)</b>                          | <b>(491.19)</b>                            |
| <b>C Cash flow from financing activities</b>                          | <b>2,155.89</b>                            | <b>(172.46)</b>                            |
| <b>Net increase / (decrease) in cash and cash equivalents (A+B+C)</b> | <b>(34.86)</b>                             | <b>(128.91)</b>                            |
| Cash and cash equivalents at the beginning of the year                | 111.97                                     | 178.43                                     |
| <b>Cash and cash equivalents at the end of the year</b>               | <b>77.11</b>                               | <b>49.52</b>                               |
| <b>Components of Cash and cash equivalents</b>                        |  |  |
| Cash on hand  | 14.23                                      | 18.53                                      |
| Balances with banks   |  |  |
| - on current accounts   | 62.88                                      | 30.99                                      |
| <b>Total Cash and Cash Equivalents</b>                                | <b>77.11</b>                               | <b>49.52</b>                               |

*H*

*3/8*

